Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 6Lymphoma 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Burkitt Lymphoma 2Breast Neoplasms 2Vasculitis 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1Recurrence 1Pancreatic Neoplasms 1Osteomyelitis 1Nose Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Pulmonary Nodules 1Metastatic Solid Tumors 1Lymphoproliferative Disorders 1

Interventions

sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Tomography, X-Ray Computed 1Nivolumab 1Ipilimumab 1Electrocardiography 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Solid Tumors × Tomography, X-Ray Computed × Clear all
NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡